390 related articles for article (PubMed ID: 37751134)
21. Development of JmjC-domain-containing histone demethylase (KDM2-7) inhibitors for cancer therapy.
Zhang L; Chen Y; Li Z; Lin C; Zhang T; Wang G
Drug Discov Today; 2023 May; 28(5):103519. PubMed ID: 36754142
[TBL] [Abstract][Full Text] [Related]
22. Role of Lysine-specific Demethylase 1 and Its Small Molecule Inhibitors in Glioblastoma Multiforme Therapy.
Mitra R; Ayyannan SR
Anticancer Agents Med Chem; 2022; 22(18):3062-3085. PubMed ID: 35593350
[TBL] [Abstract][Full Text] [Related]
23. The epigenetic promotion of osteogenic differentiation of human adipose-derived stem cells by the genetic and chemical blockade of histone demethylase LSD1.
Ge W; Liu Y; Chen T; Zhang X; Lv L; Jin C; Jiang Y; Shi L; Zhou Y
Biomaterials; 2014 Jul; 35(23):6015-25. PubMed ID: 24794925
[TBL] [Abstract][Full Text] [Related]
24. A Systematic Review of Histone Lysine-Specific Demethylase 1 and Its Inhibitors.
Zheng YC; Ma J; Wang Z; Li J; Jiang B; Zhou W; Shi X; Wang X; Zhao W; Liu HM
Med Res Rev; 2015 Sep; 35(5):1032-71. PubMed ID: 25990136
[TBL] [Abstract][Full Text] [Related]
25. Novel histone demethylase LSD1 inhibitors selectively target cancer cells with pluripotent stem cell properties.
Wang J; Lu F; Ren Q; Sun H; Xu Z; Lan R; Liu Y; Ward D; Quan J; Ye T; Zhang H
Cancer Res; 2011 Dec; 71(23):7238-49. PubMed ID: 21975933
[TBL] [Abstract][Full Text] [Related]
26. [Histone demethylase LSD1 and its biological functions].
Shao GB; Huang XJ; Gong AH; Zhang ZJ; Lu RZ; Sang JR
Yi Chuan; 2010 Apr; 32(4):331-8. PubMed ID: 20423886
[TBL] [Abstract][Full Text] [Related]
27. Structural insight into inhibitors of flavin adenine dinucleotide-dependent lysine demethylases.
Niwa H; Umehara T
Epigenetics; 2017 May; 12(5):340-352. PubMed ID: 28277979
[TBL] [Abstract][Full Text] [Related]
28. Nucleosome Binding by the Lysine Specific Demethylase 1 (LSD1) Enzyme Enables Histone H3 Demethylation.
Dhall A; Shelton PMM; Delachat AM; Leonen CJA; Fierz B; Chatterjee C
Biochemistry; 2020 Jul; 59(27):2479-2483. PubMed ID: 32567837
[TBL] [Abstract][Full Text] [Related]
29. Lysine-specific histone demethylase 1 (LSD1): A potential molecular target for tumor therapy.
Chen Y; Jie W; Yan W; Zhou K; Xiao Y
Crit Rev Eukaryot Gene Expr; 2012; 22(1):53-9. PubMed ID: 22339659
[TBL] [Abstract][Full Text] [Related]
30. The Role of LSD1 and LSD2 in Cancers of the Gastrointestinal System: An Update.
Malagraba G; Yarmohammadi M; Javed A; Barceló C; Rubio-Tomás T
Biomolecules; 2022 Mar; 12(3):. PubMed ID: 35327654
[TBL] [Abstract][Full Text] [Related]
31. LSD1 in drug discovery: From biological function to clinical application.
Liu HM; Zhou Y; Chen HX; Wu JW; Ji SK; Shen L; Wang SP; Liu HM; Liu Y; Dai XJ; Zheng YC
Med Res Rev; 2024 Mar; 44(2):833-866. PubMed ID: 38014919
[TBL] [Abstract][Full Text] [Related]
32. KDM1A microenvironment, its oncogenic potential, and therapeutic significance.
Ismail T; Lee HK; Kim C; Kwon T; Park TJ; Lee HS
Epigenetics Chromatin; 2018 Jun; 11(1):33. PubMed ID: 29921310
[TBL] [Abstract][Full Text] [Related]
33. Drug discovery of histone lysine demethylases (KDMs) inhibitors (progress from 2018 to present).
He X; Zhang H; Zhang Y; Ye Y; Wang S; Bai R; Xie T; Ye XY
Eur J Med Chem; 2022 Mar; 231():114143. PubMed ID: 35101649
[TBL] [Abstract][Full Text] [Related]
34. Epigenetic regulation of epithelial to mesenchymal transition by the Lysine-specific demethylase LSD1/KDM1A.
Ambrosio S; Saccà CD; Majello B
Biochim Biophys Acta Gene Regul Mech; 2017 Sep; 1860(9):905-910. PubMed ID: 28720390
[TBL] [Abstract][Full Text] [Related]
35. Histone demethylase Lsd1 represses hematopoietic stem and progenitor cell signatures during blood cell maturation.
Kerenyi MA; Shao Z; Hsu YJ; Guo G; Luc S; O'Brien K; Fujiwara Y; Peng C; Nguyen M; Orkin SH
Elife; 2013 Jun; 2():e00633. PubMed ID: 23795291
[TBL] [Abstract][Full Text] [Related]
36. Lysine-specific histone demethylase 1 inhibitors control breast cancer proliferation in ERα-dependent and -independent manners.
Pollock JA; Larrea MD; Jasper JS; McDonnell DP; McCafferty DG
ACS Chem Biol; 2012 Jul; 7(7):1221-31. PubMed ID: 22533360
[TBL] [Abstract][Full Text] [Related]
37. Promising natural lysine specific demethylase 1 inhibitors for cancer treatment: advances and outlooks.
Li ZR; Gu MZ; Xu X; Zhang JH; Zhang HL; Han C
Chin J Nat Med; 2022 Apr; 20(4):241-257. PubMed ID: 35487595
[TBL] [Abstract][Full Text] [Related]
38. Assessing histone demethylase inhibitors in cells: lessons learned.
Hatch SB; Yapp C; Montenegro RC; Savitsky P; Gamble V; Tumber A; Ruda GF; Bavetsias V; Fedorov O; Atrash B; Raynaud F; Lanigan R; Carmichael L; Tomlin K; Burke R; Westaway SM; Brown JA; Prinjha RK; Martinez ED; Oppermann U; Schofield CJ; Bountra C; Kawamura A; Blagg J; Brennan PE; Rossanese O; Müller S
Epigenetics Chromatin; 2017; 10():9. PubMed ID: 28265301
[TBL] [Abstract][Full Text] [Related]
39. Inhibitors of enzymes catalyzing modifications to histone lysine residues: structure, function and activity.
Lillico R; Stesco N; Khorshid Amhad T; Cortes C; Namaka MP; Lakowski TM
Future Med Chem; 2016 May; 8(8):879-97. PubMed ID: 27173004
[TBL] [Abstract][Full Text] [Related]
40. Lysine-Specific Demethylase 1 (LSD1)-Mediated Epigenetic Modification of Immunogenicity and Immunomodulatory Effects in Breast Cancers.
Lee DY; Salahuddin T; Iqbal J
Curr Oncol; 2023 Feb; 30(2):2127-2143. PubMed ID: 36826125
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
